Related references
Note: Only part of the references are listed.Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy
George P. Canellos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
Christian Furth et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe et al.
BLOOD (2008)
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Ferme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
P. L. Zinzani et al.
ANNALS OF ONCOLOGY (2006)
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma:: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials
Evert M. Noordijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment
Antonio Rueda et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
RM Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
M Hutchings et al.
ANNALS OF ONCOLOGY (2005)
ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results
G Bonadonna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
